The ovarian data look pretty good on a cursory examination. But note that EXEL has been citing such efficacy metrics as unconfirmed partial responses and “disease control” rates, which have been mentioned from time to time on this board as red flags.
XL184 might yet turn out to be a fine drug; however, I think the recent accolades on various message boards are somewhat premature.
Market Data 
Markets 
AI
